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Lay summary: 
Therapy with mesenchymal stromal cells (MSCs) has been proposed as a mean to improve 
results of solid organ transplantation. One of the potential MSC role could be to induce 
tolerance after liver transplantation, i.e. allowing the cessation of several medications with 
severe side effects. This study is the first-in-man use of MSC therapy in 10 liver transplant 
recipients. This study did not show toxicity after a single MSC infusion but it was not 
sufficient to allow withdrawal of immunosuppression. 
 






Background & aim: Mesenchymal stromal cell (MSC) infusion could be a mean to establish 
tolerance in solid organ recipients. The aim of this prospective, controlled, phase-1 study was 
to evaluate the feasibility, safety and tolerability of a single infusion of MSCs in liver 
transplant recipients.  
Methods: Ten liver transplant recipients under standard immunosuppression received 1.5-
3x106/kg third-party unrelated MSCs on post-operative day 3±2, and were prospectively 
compared to a control group of 10 liver transplant recipients. As primary end-points, MSC 
infusional toxicity was evaluated, and infectious and cancerous complications were 
prospectively recorded until month 12 in both groups. As secondary end-points, rejection rate, 
month-6 graft biopsies, and peripheral blood lymphocyte phenotyping were compared. 
Progressive immunosuppression weaning was attempted from month 6 to 12 in MSC 
recipients. 
Results: No variation in vital parameters or cytokine release syndrome could be detected 
during and after MSC infusion. No patient developed impairment of organ functions 
(including liver graft function) following MSC infusion. No increased rate of opportunistic 
infection or de novo cancer was detected. As secondary end-points, there was no difference in 
overall rates of rejection or graft survival. Month-6 biopsies did not demonstrate a difference 
between groups in the evaluation of rejection according to the Banff criteria, in the fibrosis 
score or in immunohistochemistry (including Tregs). No difference in peripheral blood 
lymphocyte typing could be detected. The immunosuppression weaning in MSC recipients 
was not successful. 
Conclusions: No side effect of MSC infusion at day 3 after liver transplant could be detected, 
but this infusion did not promote tolerance. This study opens the way for further MSC or 





Liver transplantation (LT) has become the gold standard treatment of many hepatic end-stage 
diseases. Long-term graft and patient survivals are now common after LT, but recipients are 
still submitted to life-long immunosuppression, which impairs quality of life and might 
reduce survival by promoting cancer development or by increasing the risks for infection, 
kidney function impairment and cardiovascular diseases. There is therefore a need for 
improvement in the immunosuppressive protocols after LT. Finding a way to establish donor-
specific immunological tolerance without the need for non-specific immunosuppression 
remains one of the major goals in transplantation medicine [1]. 
Mesenchymal stromal cells (MSCs) are multipotent progenitors within the bone marrow, 
capable of differentiating into various cells and tissues, such as chondrocytes, osteoblasts and 
adipocytes [2]. MSCs can be isolated after ex vivo culture of the adherent mononuclear bone 
marrow cell fraction. In addition to the bone marrow, MSCs reside in the connective tissues 
of many organs including the liver. After ex vivo expansion, human MSCs have a fibroblastic-
like morphology, and are uniformly positive for SH2, SH3, CD29, CD44, CD71, CD90, 
CD105, CD106, CD120a, CD124, and CD166, but are negative for common hematopoietic 
markers such as CD14, CD45 or CD34 [2]. Human MSCs express HLA-class I and can be 
induced to express HLA-class II by IFN-γ. A large number of in vitro and in vivo studies have 
documented the anti-inflammatory and immunoregulatory properties of MSCs on both the 
adaptive and innate immune system [3], as well as a potential beneficial effect in ischemia-
reperfusion injury [4, 5]. Specifically, MSCs have been shown to decrease effector T-cell 
response while promoting the emergence of regulatory T-cells (Treg) [6]. These MSC 
properties suggest that they could be particularly attractive in solid organ transplantation 
(SOT) [7, 8], and a consortium of European academic centres studying this subject has been 
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created (http://www.misot.eu). A first randomized controlled trial evaluating the effects of 
autologous MSCs in living related kidney transplantation has been performed in China [9]. In 
this study, MSCs significantly correlated with fewer acute rejections, a lower risk of 
opportunistic infections and a better renal function at 1 month. Furthermore, fewer adverse 
effects were seen in the MSC groups compared to the control group [9]. Compared to other 
transplanted organs, the liver graft is immunologically protected, and LT recipients are 
considered the ideal candidates for MSC therapy and for operative tolerance trials after SOT 
[10]. To date there has been no published trial evaluating MSC infusion in a series of LT 
patients [1]. 
Despite the absence of major adverse effects in the preliminary clinical trials evaluating 
MSC-based therapy to date [11], clinical infusion of MSCs might theoretically be 
complicated by impairment of pulmonary function due to MSC embolism in the lung 
vasculature [12] and by a cytokine-release syndrome [13]. In addition, as MSCs are 
potentially immunosuppressive, another concern is the potential emergence of higher rates of 
opportunistic infections and induced cancers after MSC infusion in SOT recipients under 
immunosuppression. In a small European clinical series, MSC infusion in kidney recipients 
was associated with transient renal dysfunction [14] and opportunistic infections [15]. It is 
also possible that MSC injection promotes liver fibrosis [16]. Finally, in vitro MSC expansion 
and culture might generate genomic instability and chromosomal aberrations with a potential 
risk of MSC neoplastic transformation [17, 18].  
The aim of this study was to evaluate the feasibility, the safety and the tolerability of a single 
MSC infusion after LT in a first-in-man, prospective, controlled, phase-1 study. The primary 
endpoints were set to clinically detect potential side effects of MSC infusion, as well as the 
occurrence of infectious and malignant complications. As secondary end-points, the potential 
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immune-regulative effects of MSCs and the impact of MSCs on Treg counts and phenotype 
were analysed by comparison with a control group. In addition, in a second step, progressive 
immunosuppressive withdrawal was attempted as a phase 2 study in stable patients who 




This study was a monocentric, prospective, non-randomized, controlled, open-label trial. 
Protocol inclusion and exclusion criteria are presented in Table 1. Between March 2012 and 
February 2014, 10 stable and low-risk LT recipients under standard immunosuppression 
received 1.5-3x106/kg third-party MSCs on post-operative day 3±2 (MSC group). These 
patients were prospectively compared to a control group of 10 LT recipients who fulfilled the 
study inclusion criteria, declined to receive MSCs, but accepted to be included in the trial as 
control patients during the same period (Control group). In addition, in patients from the MSC 
group who did not develop rejection and had normal graft function and month-6 graft biopsy, 
progressive weaning of immunosuppression was attempted (Fig 1). Weaning of 
immunosuppression was not considered in the control group as it is well established that early 
(<1 year) immunosuppression withdrawal is not possible and unethical in LT recipients under 
regular immunosuppression protocols. The study protocol conformed to the ethical guidelines 
of the 1975 Declaration of Helsinki and was approved by the local Ethics Committee and by 
the Belgian Federal Agency for Medicines and Health Products (Eudract # 2011-001822-81). 
The study was registered at ClinicalTrials.gov (protocol # NCT 01429038). Written informed 
consent was obtained from each MSC donor and LT patient.  
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Liver transplant procedures and postoperative management 
The following deceased liver graft donor characteristics were prospectively collected: age, 
gender, donation after brain or circulatory death, Eurotransplant donor risk index (ET-DRI) 
[19], cause of brain damage, terminal blood sodium level, terminal liver function tests, need 
for vasopressors, length of intensive care unit stay, body mass index (BMI), last 24-hour 
diuresis, and past cardiopulmonary resuscitation.  
The LT procedures were regular deceased LT as performed in the authors’ centre [20, 21]. 
The following LT recipient characteristics were collected: age, gender, BMI, LT indication, 
and the laboratory Model for End-Stage Liver Disease (MELD) score at admission for 
transplantation. Cold and total graft ischemic times were recorded. The immunosuppressive 
regimen consisted of a triple therapy of tacrolimus, mycophenolate mofetyl (MMF) and 
steroids. The tacrolimus dose was adapted according to through whole blood values (between 
8 and 12 ng/ml the first 28 days and between 5 and 8 thereafter) until day 180 in both groups. 
In the MSC group, if a rejection episode had not been suspected based on the liver tests and 
month 6 biopsy, tacrolimus was progressively tapered from day 180 to be discontinued by day 
270 in the absence of rejection (Fig 1). A graft biopsy was performed at day 270±15 in the 
MSC group. MMF was administered orally from day 1 through day 270 at the dose of 500 mg 
bid. In the MSC group, if the patient did not develop rejection during tacrolimus withdrawal 
and at day 270 graft biopsy, MMF was progressively tapered and definitely discontinued by 
day 365 in the absence of rejection (Fig 1). Steroid treatment consisted of administration of 
methylprednisolone 500 mg iv before liver graft reperfusion, followed by progressively 
decreasing daily doses until progressive withdrawal during month 1 (Fig 1). Liver graft 
rejection was assessed according to standard criteria, including clinical symptoms, blood liver 
enzymes, and liver graft biopsy if needed. Therapy for rejection included an increase in 
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tacrolimus administration, boluses of methylprednisolone 500 mg iv per day for 3 days, and 
anti-thymocyte globulins in steroid-resistant rejection, if needed. 
Antibacterial and antiviral prophylaxis was standardized between groups including 
cefuroxime 3 x 1.5g or piperacillin-tazobactam 4 x 4 g/d for 5 days, prevention of 
pneumocystis (co-trimoxazole 500 mg po 1/d for three months) and of cytomegalovirus 
(CMV) infection if indicated (D+, R-, 100 days of valgancyclovir 2 x 450 mg/d po). 
MSC donors 
Inclusion criteria for MSC donors included: unrelated to the recipient; aged >18 years; no 
human leucocyte antigen (HLA) matching required; fulfilling generally accepted criteria for 
allogeneic hematopoietic stem cell donation; and informed consent given. Exclusion criteria 
were: known allergy to lidocaine; any risk factor for transmissible infectious diseases; 
meeting generally accepted exclusion criteria for allogeneic hematopoietic stem cell donation 
[22]. 
MSC production 
MSC expansion cultures were performed and evaluated at the Laboratory of Cell and Gene 
Therapy (LTCG) of the University Hospital of Liege, CHU of Liege, as previously described 
[22, 23]. Briefly, bone marrow (BM) (30-50 mL) was collected under local anaesthesia in 
sterile conditions, and put in sterile heparin-containing syringes. Mononuclear BM cells were 
isolated by Ficoll (GE Healthcare-Amersham Biosciences AB, Upsala, Sweden), seeded in 
sterile tissue culture flasks (BD Falcon, Bedford, MA), and cultured in Dulbecco’s Modified 
Eagles Medium-Low Glucose (Invitrogen, Merelbeke, Belgium) with glutamate 
supplemented with 10% irradiated fetal bovine serum (Hyclone- Perbio Science, Merelbeke, 
Belgium) and antibiotics (penicillin/streptomycin, Lonza Bio Science, Verviers, Belgium). 
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Cultures were maintained at 37 °C in humidified atmosphere containing 5% CO2 for a total of 
about 4 weeks. The medium was replaced twice a week and, after approximately 2 weeks, the 
cultures were near confluence (>70%). Cells were then detached by treatment with irradiated 
trypsin-EDTA (Invitrogen, Merelbeke, Belgium) and replated (passaged) at a lower density to 
allow further expansion. A second passage was performed when the cells reached confluence 
again (>70%). At confluence, the cells were harvested, washed, and re-suspended using 
phosphate-buffered saline (PBS)-EDTA (Miltenyi Biotec, Utrecht, The Netherlands) and 
Human Serum Albumin (HSA) (CDF-CAF, Brussels, Belgium). The MSCs were then frozen 
in a medium containing 70% PBS, 20% HSA, and 10% DMSO (WAK-Chemie, Steinbach, 
Germany) using standard techniques. Before infusion, the MSCs were thawed and diluted in 
PBS, and then injected into the patients within 60 minutes. All reagents were certified sterile, 
and endotoxin-free, and had been used in other clinical trials in Europe. In addition, the batch 
of fetal bovine serum used was selected after extensive testing, and was irradiated to ensure 
removal of all potential viruses. The following analyses were performed as quality controls 
for each MSC expansion culture: nucleated cell count on a manual cell counter, flow 
cytometry analysis with determination of the % cells (out of total cells) positive for CD73, 
CD90, and CD105, and negative for HLA-DR, CD31, CD80, CD14, CD45, CD3, and CD34; 
cell viability using trypan blue exclusion; microbiology testing, including standard virology, 
bacterial culture, and search for mycoplasma; endotoxin detection using the limulus test; and 
cytogenetics. MSC potency was evaluated by determining the percentage inhibition of T-cell 
proliferation in Mixed-Lymphocyte Reaction (MLR) essay. Finally, MSC differentiation into 
adipocytes, osteocytes, and chondrocytes was validated in preliminary experiments [22].  
MSC infusion 
Third-party unrelated MSC infusion was performed on post-transplant day 3±2 through a 
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central intravenous line in fully monitored, stable, conscious and extubated patients who were 
receiving standard LT recipient care, after liver Doppler ultrasonography confirming arterial 
and portal flows. MSC infusion had to be performed within 60 min of thawing, with two 
investigators at the patients’ bedside.  
Primary endpoints 
- MSC infusional toxicity: the duration and volume of the MSC infusion were noted. To 
assess pulmonary and systemic toxicity of MSC infusion, tympanic body temperature, heart 
rate, mean arterial blood pressure and peripheral capillary oxygen saturation (SpO2) were 
recorded 5 min before infusion, after 15 minutes and at the end of the MSC infusion. Clinical 
signs of allergy, such as skin reaction or anaphylactic shock, were also recorded. 
- MSC infectious and cancerous complications: the incidence, timing and severity of any 
infections (bacterial, viral, fungal) and any malignant diseases were prospectively recorded 
until month 12 in both groups. 
Secondary endpoints 
Patient and graft survivals and biopsy-proven graft rejection rates were prospectively 
recorded in both groups until month 12. Liver graft function (bilirubin, liver enzymes, 
international normalized ratio (INR)), kidney function (creatinine), C-reactive protein (CRP) 
and tacrolimus levels were compared using standard clinical blood tests at day 7 and months 
1, 3, and 6. Blood immunoglobulin levels were compared at months 1 and 6.  
Liver graft biopsy and immunohistochemistry  
Month-6 formalin-fixed, paraffin-embedded graft biopsies were blindly analysed by two 
gastrointestinal pathologists (N.B., J.S), who described fibrosis and signs of graft rejection 
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according to the Banff criteria [24].  Paraffin-embedded sections of liver biopsy specimens (4 
µm thick) underwent immunostaining using an automated immunostainer (Ventana Medical 
Systems, Tucson, AZ) with antibodies directed against human CD3, CD4, CD8, CD20, 
CD138, CD68, CD1a and FoxP3. An amplification kit (Ventana Medical Systems) and a 
detection system including diaminobenzidine (Ventana Medical Systems) as a chromogen 
were used during the automated procedure. Archival lymph node sections were used as 
positive controls. For negative controls, the primary antibody was omitted. The mean number 
of positive cells in each patient was calculated by counting these cells (original magnification, 
x400) in the three most cellular microscopic fields, also called hot spots. 
Peripheral blood lymphocyte immunophenotyping and CD4 phenotyping 
Peripheral blood mononuclear cells were phenotyped on days 30, 90 and 180 using 4-color 
flow cytometry after treatment with a red blood cell lyzing solution as described [25]. The 
analyzed cell subsets were T cells (CD3+), CD4+ T cells (CD3+CD4+lymphocytes), CD8+ T 
cells (CD3+CD8+ lymphocytes), naïve CD4+ T cells (CD4+CD45RAhigh lymphocytes), 
memory CD4+ T cells (CD4+CD45RO+ lymphocytes), NK cells (CD3−CD56+ lymphocytes), 
as well as B cells (CD19+ lymphocytes). The percentage of positive cells was measured 
relative to total nucleated cells, after subtraction of nonspecific staining. Absolute counts were 
obtained by multiplying the percentages of positive cells by the white blood cell counts 
(Advia 120 hematology analyzer, Bayer Technicon). 
More detailed CD4+ T cell phenotyping was performed on days 0 (before LT), 30 and 90 as 
previously reported [19].  Tregs were defined as CD4+CD25+CD127dimFOXP3+ lymphocytes 
while remaining CD4+ T cells were considered as conventional T cells (Tconvs). Naive Tregs 
were defined as CD45RA+HLA-DRneg Tregs, and activated effector Tregs were defined as 
CD45RAnegHLA-DR+ Tregs as previously reported [26]. T cell proliferation was assessed by 
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KI67 expression, and IL-2 signaling was estimated by quantifying the expression of 
phosphorylated STAT5 (phosphoSTAT5) [27].  The following antibodies specific for human 
epitopes were used: CD4-APC (RPA-T4), CD25-PeCy7 (BC96, Sony), CD127-biotin 
(eBioRDR5), CD45RA-BV510 (HI100,BD), HLA-DR-PE (L243), FOXP3-AlexaFluor488 
(259D, Biolegend, ImTech Antwerp, Belgium), posphoSTAT5-BV421 (pY694,BD), Ki67-
PercPCy5.5 (B56, BD) and anti-streptavidin APCCy7 (all from eBioscience, unless otherwise 
indicated). Samples from patients were thawed and washed with staining buffer. One million 
cells of each sample were then incubated with surface antibodies for 20 min at 4°C in the dark 
and washed with staining buffer. This process was repeated for a 15-minute period for the 
streptavidin staining step. Then, samples were permeabilized using the PerFix EXPOSE 
(Beckman Coulter, Brea, CA) according to the manufacturer’s instructions and as previously 
reported [26]. Data were acquired using a FACS Canto II (Becton Dickinson) and were 
analyzed with FlowJo v7.6.5 (Treestar Inc., San Carlos, CA).  
 
Statistical analysis 
Data are presented as median values and ranges, and the difference between groups was 
evaluated by the Mann-Whitney test. Proportions were analysed using Fischer’s test. 
Differences between repeated measures were evaluated by one-way ANOVA using the 
Friedman test as a post-hoc test. Survival rates were calculated with the Kaplan-Meier method 
and compared with the log-rank (Mantel-Cox) test. A value of P<0.05 was considered 
significant. Data were analysed using Prism 6.0c software for Macintosh OSX (GraphPad 
Software, San Diego, CA).   
Results 
Liver transplantation donor and recipient characteristics 
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No statistical difference could be detected between the MSC and control groups concerning 
the characteristics of both liver graft donors and recipients (supplementary material).  
Primary endpoints 
a) MSC infusional toxicity. 
On day 3 (2-5), the 10 MSC patients received 2.1 106/kg (1.9-2.7) MSC, representing a 
perfusion volume of 341 mL (302-614). Median duration of infusion was 25 min (11-60). No 
variation in vital parameters or cytokine release syndrome could be clinically detected during 
and after MSC infusion (Table 2). No MSC patient developed clinical signs of allergy or 
impairment of vital functions (including liver graft function) within the week following MSC 
infusion.  
b) Infectious and cancerous complications. 
No patient in either group developed life-threatening opportunistic infection or de novo cancer 
(including post-transplant lymphoproliferative disease) during follow-up. There was no 
difference in overall rates of infection between the two groups (Table 3). In the MSC group, 
two patients developed labial herpetic infections successfully treated by oral acyclovir. In 
addition, two MSC patients at high risk of CMV (D+, R-) developed asymptomatic CMV 
seroconversion under valganciclovir therapy. No patients developed CMV disease. Two 
patients transplanted for hepatocellular carcinoma (HCC) complicating cirrhosis had a 
pejorative pathology report and developed HCC recurrence: one MSC patient had a R1 LT 
with a HCC nodule invading the diaphragm (he died from HCC recurrence at month 10) and 
one control patient had an unsuspected neoplastic thrombus in a supra-hepatic vein at liver 
pathology (still alive at 5-year follow-up after HCC recurrence at month 23 and resection of 




No patient required retransplantation during the first year of follow-up. One patient from the 
control group died at day 16 from a hypovolemic shock induced by a fistula between the 
hepatic artery and the bile duct, probably due to an infected pseudoaneurysm. Six-month graft 
and patient survivals were 100% and 90% in the MSC and control group, respectively (NS). 
One-year graft and patient survivals were 90% in both groups (NS). No patient in either group 
developed biopsy-proven rejection during the first 6 months of follow-up. Protocol month-6 
biopsies did not demonstrate a difference between groups in the evaluation of the Banff 
criteria, the fibrosis score or the immunohistochemistry (Table 4; Fig S1 and Fig S2 in 
supplementary material). No difference could be detected in liver graft or kidney function 
between the two groups during the 6 months of comparison (Table 5; Fig S3 in supplementary 
material). No difference in peripheral blood lymphocyte phenotyping could be detected on 
day 30, 90 and 180 (Table 6; Fig S4 in supplementary material).  
Impact of MSCs on peripheral blood CD4+ T cells (including Tregs) 
The 2 groups of patients had similar counts of peripheral blood CD4+ T cells and Tconvs on 
days 0, 30 and 90 after transplantation (Fig 2 A-B). As shown in Fig 2 C-F, Treg counts and 
phenotype (naive versus resting versus activated) were comparable in the 2 groups of patients 
at each time point. Furthermore, Treg as well as Tconv proliferation (assessed by KI67 
expression) was also similar in the 2 groups of patients, as were the levels of phosphoSTAT5 
in Tregs (the latter translating similar IL-2 signalling in Tregs). These combined observations 
suggest that a single MSC infusion had no impact on Treg count or phenotype in this study. 
Immunosuppression withdrawal in the MSC group 
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One patient from the MSC group was excluded from immunosuppression withdrawal attempt 
due to HCC recurrence, but the nine others met the necessary criteria. In one patient, 
tacrolimus and MMF withdrawal was performed without rejection and she remained off 
immunosuppression for 12 months. In two patients, MMF monotherapy was achieved at 
month 9, but graft rejection occurred during MMF withdrawal and was successfully treated by 
tacrolimus reintroduction. In 6 patients, the transaminases significantly increased during 
tacrolimus withdrawal. In these cases, withdrawal was cancelled and liver tests normalised 
after increase of the tacrolimus dose. 
Discussion 
This phase 1, prospective, controlled study is the first to evaluate the feasibility, safety and 
tolerability of MSC infusion in a series of 10 LT patients under classical tacrolimus-based 
immunosuppression. In these patients, a post-transplantation intravenous 1.5-3x106/kg MSC 
infusion was well tolerated, without evidence of pulmonary dysfunction or of cytokine-release 
syndrome. This dosing was chosen according to the authors’ experiences with MSC infusion 
after HSC transplantation [23, 28]. These LT patients receiving MSC did not develop any 
evidence of impairment in vital organ functions, including the liver graft and the kidneys. In 
addition, they did not suffer from an increased susceptibility to infections.  No de novo cancer 
was detected after one year of follow-up, and a HCC recurrence was observed in a patient 
with a very poor prognosis due to unexpected extra-hepatic HCC spread discovered during 
LT. For all these primary endpoints, the LT recipients who received MSCs did not react 
differently compared to patients in the control group. This finding is an important step in the 
evaluation of the potential role of MSCs in SOT recipients, and particularly after LT. 
In the last decade, MSCs have been extensively studied both in vitro and in vivo. Their anti-
inflammatory and immunoregulatory properties [29] [3], added to potential beneficial effects 
on ischemia/reperfusion injury [5], might select MSCs as a potential future therapy for SOT 
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recipients in whom life-long immunosuppression and chronic allograft dysfunction still 
impair quality of life and graft survival. However, as the clinical use of MSCs is still under 
evaluation in preliminary trials in non-transplant patients, their potential secondary effects 
need to be carefully assessed in SOT recipients. Due to their size, MSCs are known to 
embolize within the pulmonary circulatory bed when they are infused in the peripheral or 
central venous circulation of mice [12]. There is therefore a theoretical risk of decreased 
pulmonary exchange after MSC infusion, but this complication has not been reported so far in 
the early phase clinical trials nor in the randomized study in living-related kidney 
transplantation performed in China [9]. As reported previously by our group, MSC infusion in 
hematopoietic stem cell transplant recipients has not been associated with any infusional 
toxicity [23], nor with long-term impairment of lung function [28]. This was confirmed in the 
current trial, as our 10 patients receiving MSCs did not develop any sign of pulmonary 
dysfunction. In addition, this study did not observe any suspicion of allergy or cytokine-
release syndrome, or of any other possible complications concerning the liver graft or extra-
hepatic organ function. In a preliminary evaluation in 2 kidney recipients, possible toxicity of 
MSC infusion on kidney graft function was suggested [14], but this “engraftment syndrome” 
was not detected in our cohort of LT recipients or in any other MSC clinical trial to date. 
As MSCs are immunosuppressive, SOT recipients who receive MSCs in addition to standard 
immunosuppression could be over-immunosuppressed and develop higher rates of 
opportunistic infections [26]. Again, in a small series of kidney recipients, opportunistic 
infections were observed after MSC treatment [15]. On the contrary, in the largest experience 
reported so far of MSC infusion after living-related kidney transplantation, MSC recipients 
developed fewer infectious complications than controls [9]. In our series, the MSC patients 
did not develop life-threatening infections, and no difference could be detected in comparison 
with the control group.  
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It has been suggested in in vitro experiments that MSCs might carry a potential for cancerous 
degeneration [17]. This potential risk has so far not been demonstrated in the preliminary 
MSC clinical experiences in either SOT or in non-SOT patients, and no patient in our series 
had developed de novo cancer after one-year follow-up. This important issue needs to be 
confirmed by further follow-ups of this series and by further experience in larger series. 
Furthermore, in the series described here, one patient died from early HCC recurrence after a 
R1 LT with a very bad prognosis. The authors do not consider that HCC within Milan criteria 
should be excluded for further MSC trials in LT, but the possibility of an increased risk of 
HCC recurrence after MSC infusion cannot be excluded by this preliminary phase 1 study. 
As secondary end-points, this study prospectively evaluated the possible effects of a single 
infusion of MSCs on LT recipient immunity by comparison with a control group. No 
difference could be detected between the MSC and control groups on graft rejection episodes, 
opportunistic infection rates, graft histology and immunohistochemistry at day 180 and on 
peripheral blood CD4+ T-cell subsets. Particularly, no impact of MSC infusion on Tconv 
counts/proliferation was demonstrated, suggesting that MSCs did not impact T-cell immunity 
while, in contrast to what has been observed in mice [30], MSC infusion did not influence 
Treg number, proliferation or phenotype in this cohort of patients. This finding might indicate 
that a single infusion of MSCs in LT patients receiving tacrolimus and MMF will not modify 
their immunity status. As MSCs and immunosuppressive drugs inhibit the same targets 
(essentially T cells), it is reasonable to consider that interactions between them can occur. The 
current standard of immunosuppression after LT is a triple therapy associating low-dose 
steroids, MMF and tacrolimus, with rapid steroid weaning. In vitro, some authors have shown 
that tacrolimus and rapamycin might decrease MSC immunosuppressive properties [31], and 
conversely, that MSCs might reduce the immunosuppressive capacities of tacrolimus and 
rapamycin. Such an effect has not been found with mycophenolic acid (MPA), an MMF 
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metabolite. Moreover, a high dose of tacrolimus seems to be toxic for MSCs, while MPA and 
rapamycin at a therapeutic dose just inhibit MSC proliferation [32]. Furthermore, it has been 
demonstrated that MPA and MSCs have a synergistic immunosuppressive effect [32]. In vivo, 
MPA and MSCs also synergize to promote long-term allograft tolerance in rat heart 
transplantation [33]. As Tregs probably play an important role in MSC-mediated 
immunomodulatory effects, it is important to confirm that such a combination therapy is also 
favorable for Treg expansion. Hence, a recent study supported that mTOR inhibitor-based 
immunosuppression favours survival of Tregs after administration in a nonhuman primate 
model, whereas tacrolimus does not [34]. 
In addition, in a phase 2 part of this study, patients from the MSC group underwent 
unsuccessful progressive immunosuppression weaning. Induction of operational tolerance is a 
major goal in SOT and particularly in LT patients [1]. Operational tolerance is a rare 
phenomenon after LT [18]. Tregs have been proposed to be key in strategies aiming for 
tolerance and immunomodulation after SOT [35]. In a recent paper, Todo et al. demonstrated 
that a single Treg injection might promote operational tolerance after living-related LT [36]. 
Recently, it has been demonstrated both in vitro and in vivo that MSCs could promote Treg 
expansion by their effects on immature dendritic cells [37]. In this study, the authors were not 
able to show that a single infusion of MSCs at day 3 after deceased LT could promote Treg 
expansion, Treg infiltration of the liver graft at biopsy at day 180, or operational tolerance. 
There are many shortcomings to this study. First, it is clear that this first study in 10 LT 
recipients does not prove the safety of MSC infusion in this setting. These results will have to 
be confirmed by further studies in larger groups of SOT recipients. The absence of detectable 
effects of MSCs might be due to an insufficient sample size, to the tacrolimus-based 
immunosuppressive regimen or to an insufficient MSC dosing, which should possibly be 
increased or repeated. The timing (pre-, intra- or post-operative) and the infusion routes 
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(peripheral vein, portal vein or hepatic artery) of MSC infusion should also be evaluated. 
Different sources (BM, fat tissue, liver) or donors (organ donor, organ recipient) of MSCs 
might also be tested in further studies. 
In summary, this study reported the first prospective controlled phase 1 clinical trial 
evaluating the toxicity of a MSC-based immune-regulating regimen in a series of deceased 
LT recipients receiving classical tacrolimus-based immunosuppression. In this trial, no side 
effects of MSC infusion at day 3 after transplantation could be detected. Even if no 
modification of the patient immunity and Treg expansion could be demonstrated, and even if 
immunosuppression weaning was not successful in this first series of 10 patients, this study 
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Figure 1: Scheme of the study 
MSC: Mesenchymal stromal cell; MMF: mycophenolate mofetil; MP: Methylprednisolone 
 
Figure 2: Evolution of on peripheral blood CD4+ T cells (including Tregs) on days 0, 30 
and 90 in the control (white rectangles) or MSC (grey rectangles) groups 
A. Total CD4+ T cells,  
B. Conventional CD4+ T cells (Tconv)  
C. Regulatory T cells (Tregs)  
D. Treg subsets 
E. Treg proliferation (assessed by KI67 expression)  
F. Treg IL-2 signaling (assessed through phosphoSTAT5 expression)  
 
HLA-DRposCD45RAneg (DR+RA-) Tregs refer to activated Tregs, HLA-DRnegCD45RAneg 
(DR+RA-) Tregs refer to resting Tregs and HLA-DRnegCD45RApos (DR-RA+) Tregs refer to 
naive Tregs. Plots display the median, 25th and 75th percentiles of the distribution (boxes), 
and whiskers extend to the 10th and 90th percentiles. Grey zones show normal ranges (from 5th 
to 95th percentiles) and horizontal lines the medians in 45 age-matched healthy controls. No 
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Table 1: LT recipient inclusion and exclusion criteria 
 
Inclusion criteria   
 Surgery First whole liver deceased LT (DBD or DCD) 
 Age Between 18 and 75 years 
 Graft Functioning graft at time of MSC infusion 
Graft doppler ultrasonography confirming arterial and 
portal flows 
   
Exclusion criteria   
 Surgery Re LT, partial LT, combined LT 
 Cancer Past history of cancer in the donor or recipient, with the        
exception of hepatocarcinoma within Milan criteria 
 Infection Active infection in the donor or recipient, including HIV 
and HCV 
  EBV negative (recipient) 
 Miscellaneous Auto-immune liver disease (recipient) 
  Endotracheal intubation (recipient) 




LT: Liver transplantation; DBD: donation after brain death; DCD: donation after circulatory 
death; MSC: Mesenchymal Stromal Cells; HIV: Human Immunodeficiency virus; HCV: 
Hepatitis C virus; EBV: Epstein-Barr virus 
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Table 2: Comparison of vital parameters before, during and after MSC infusion 
 
 
 Pre MSC infusion After 15 min End of MSC infusion P 
Temperature (°C) 36.1 (35.4-37.7) 36.4 (35-36.9) 36.2 (35.5-37) 0.87 
Mean arterial pressure 
(mmHg) 
103 (87-124) 107 (84-120) 106 (94-115) 0.83 
Heart rate (per min) 81 (65-102) 83 (65-102) 81 (68-101) 0.17 























MSC: Mesenchymal stromal cells; SpO2: peripheral capillary oxygen saturation  
 









Table 3: Cancerous and infectious complications (1-year follow-up) 
 





Cancer      
 Overall  1 0 > 0.99 
      
 De novo  0 0  
 HCC recurrence  1 0  
      
Infection      
 Overall  2 6 0.06 
      
 Fungal  0 0  
 Viral CMV disease 0 0  
  HSV 2 0  
  VZV 0 1  
 Other Wound 0 1  
  Urinary 0 2  
  Sinusitis 0 1  









MSC: Mesenchymal stromal cell; HCC: hepatocellular carcinoma; CMV: cytomegalovirus; 
















Banff score 3 (0-6) 4 (0-7) 0.21 
Fibrosis score 1 (0-2) 1 (0-3) 0.48 
 
CD3 196 (95-334) 162 (93-590) 0.86 
CD4 101 (54-212) 103 (17-496) > 0.99 
CD8 69 (15-196) 85 (12-300) 0.49 
CD68 28.5 (12–75) 40 (15-104) 0.58 
CD1a 1 (0-3) 1 (0-3) 0.83 
CD138 7.5 (4-38) 6 (2-44) 0.50 
CD20 27 (3-95) 28 (10-163) 0.66 






MSC: mesenchymal stromal cell  




Table 5: Postoperative laboratory tests 
 
 
 MSC group (n=10) Control group (n=9) P 
D7    
total bilirubin (mg/L) 10.2 (4.6-26.8) 8.3 (3.7-20.7) 0.21 
AST (U/L) 28.5 (19-101) 46 (30-105) 0.16 
Alcaline Ph (U/L) 140 (43-475) 256 (172-590) 0.04 
GGT (U/L) 218 (29-626) 368 (172-760) 0.24 
INR 1.14 (1-1.21) 1.06 (1-1.26) 0.16 
creatinine (mg/L) 11.55 (5.7-36) 8.9 (5.9 – 16.9) 0.32 
CRP (mg/L) 32.8 (8.4-50.1) 24.6 (12.8-144.3) 0.82 
tacrolimus (µg/L) 7.1 (3.1-9) 9 (2.1-11.7) 0.12 
D30    
total bilirubin (mg/L) 5.6 (3.4-11.6) 4.6 (1.3-7.5) 0.34 
AST (U/L) 18 (11-51) 16 (9-61) 0.48 
Alcaline Ph (U/L) 137.5 (53-554) 144 (103-857) 0.43 
GGT (U/L) 101 (26-596) 112 (42-690) 0.82 
INR 1.15 (0.97-1.26) 1.08 (1-1.19) 0.53 
creatinine (mg/L) 16.2 (5.3-24.4) 14.1 (8.2-27.6) 0.45 
CRP (mg/L) 12.9 (4.8-62.2) 17.2 (3.5-73) 0.94 
tacrolimus (µg/L) 8.1 (2.4-10) 8 (5-16.3) 0.51 
D90    
total bilirubin (mg/L) 4.8 (3-19.8) 4.3 (2.3-7.5) 0.34 
AST (U/L) 20 (14-31) 20 (11-58) 0.79 
Alcaline Ph (U/L) 101.5 (56-1461) 119 (86-570) 0.54 
GGT (U/L) 58.5 (15-695) 49 (14-332) 0.76 
INR 1.1 (0.95-1.29) 1.13 (1.01-1.56) 0.65 
creatinine (mg/L) 12.05 (5-25.7) 13.4 (7-21.7) 0.92 
CRP (mg/L) 3.1 (1-27.6) 6.8 (1.3-23.5) 0.20 
tacrolimus (µg/L) 7.7 (3.7-13) 6.4 (5.2-13.2) 0.61 
D180    
total bilirubin (mg/L) 6.6 (3.7-25.7) 4.6 (0.43-27) 0.27 
AST (U/L) 25 (15-44) 24 (14-136) 0.64 
Alcaline Ph (U/L) 143.5 (67-1,166) 186 (82-554) 0.26 
GGT (U/L) 81 (22-978) 53 (12-2,064) 0.43 
INR 1.1 (1-1.26) 1.07 (1-1.17) 0.23 
creatinine (mg/L) 11.6 (7.1-18.9) 10.1 (1.28-15.8) 0.30 
CRP (mg/L) 3.5 (0.7-36.5) 5.6 (0.9-151) 0.23 





MSC: mesenchymal stromal cells; D: day; AST: aspartate aminotransferase; Alcaline Ph : 
alcaline phosphatase ; GGT: gamma glutamil transferase; INR: international normalized ratio 
CRP: C reactive protein 
Data are presented as median and ranges; Mann-Whitney test 
 
 
Table 6: Peripheral blood lymphocyte counts  
 
 MSC group (n=10) Control group (n=9) P 
D30    
White blood cells (/µL) 6,630 (3,280-9,700) 5,190 (4,150-10,030) 0.67 
Lymphocytes (/µL) 855 (380-1,690) 940 (300-1,550) 0.92 
CD3 (/µL) 687 (288-1,406) 620 (200-1,336) 0.48 
CD45RA (/µL) 119 (50-557) 147 (48-234) 0.70 
CD45RO (/µL) 373 (179-516) 201 (79 -609) 0.23 
CD3+CD4+ (/µL) 535 230-978) 349 (128-786) 0.30 
CD3+CD56+ (/µL) 27 (1-87) 42 (4-154) 0.35 
CD3+CD8+ (/µL) 115 (49-418) 142 (57-336) 0.76 
CD19 (/µL) 144 (30-286) 99 (38-369) 0.70 
CD56 (/µL) 109 (45-365) 188 (58-618) 0.27 
D90    
White blood cells (/µL) 5,265 (970-8,160) 5,200 (2,470-7,030) 0.39 
Lymphocytes (/µL) 875 (420-1,880) 760 (490-1,760) 0.82 
CD3 (/µL) 767 (352-1,225) 553 (274-1,419) 0.30 
CD45RA (/µL) 123 (51-389) 82 (54-259) 0.58 
CD45RO (/µL) 381 (171-680) 179 (135-765) 0.23 
CD3+CD4+ (/µL) 516 (292-923) 285 (202-976) 0.27 
CD3+CD56+ (/µL) 21 (1-99) 34 (2-197) 0.76 
CD3+CD8+ (/µL) 202 (41-496) 228 (56-362) 0.94 
CD19 (/µL) 93 (34-354) 100 (21-321) 0.76 
CD56 (/µL) 154 (66-331) 119 (59-550) 0.82 
D180    
White blood cells (/µL) 4,815 (4,200-8,150) 5,440 (2,680-11,430) 0.99 
Lymphocytes (/µL) 1,250 (660-2,260) 1,000 (540-1,340) 0.23 
CD3 (/µL) 880 (395-2,098) 592 (342-1,366) 0.27 
CD45RA (/µL) 127 (76-364) 108 (61-298) 0.58 
CD45RO (/µL) 396 (214-615) 267 (156-864) 0.20 
CD3+CD4+ (/µL) 623 (348-728) 359 (224-1,163) 0.20 
CD3+CD56+ (/µL) 31 (1-91) 36 (3-117) 0.54 
CD3+CD8+ (/µL) 238 (38-1,471) 210 (73-345) 0.70 
  
 34
CD19 (/µL) 99 (25-256) 192 (52-258) 0.27 




Data are presented as median and ranges; Mann-Whitney test 
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